Puma Biotechnology, Inc. reported $231M of revenue over the trailing twelve months, −2.9% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $231M (to Q2 2026). Net income: $27M, trailing twelve months to Q2 2026. Free cash flow: $41M, trailing twelve months to Q2 2026. Operating margin: 11%, trailing twelve months to Q2 2026.

PBYIPuma Biotechnology, Inc.

Healthcare

$9.98+93% 1Y

$9.98

$4.7352 weeks$9.98

Latest close: a new 52-week highOct 8, 2026what changed →

PBYI as reported

Puma Biotechnology, Inc. reported $231M of revenue over the trailing twelve months, −2.9% on the year before. 11 reported series are charted on this page, each one as filed.

$231M

Revenue, trailing twelve months · to Q2 2026 · −2.9% against the twelve months before

Net income: $27M
Net income · −45% year on year · trailing twelve months to Q2 2026
Free cash flow: $41M
Free cash flow · −7.1% year on year · trailing twelve months to Q2 2026
Operating margin: 11%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PBYI, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$231M	−2.9%	Q2 2026
Net income	$27M	−45%	Q2 2026
EPS	$0.52	−47%	Q2 2026
Gross margin	75%	n/a	Q2 2026
Operating margin	11%	n/a	Q2 2026
Net margin	10%	n/a	Q2 2026
ROE	24%	n/a	Q2 2026
ROA	15%	n/a	Q2 2026
ROIC	45%	n/a	Q2 2026
Free cash flow	$41M	−7.1%	Q2 2026
P/E	19.2	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.